In the spotlight

New guidance on the management of liver disease in people with congenital BD

New guidance from the EAHAD, ISTH, EHC, WFH: the management of liver disease in people with congenital bleeding disorders

Experts from leading health organizations including the International Society of Thrombosis and Hemostasis (ISTH), The European Association for Haemophilia and Allied Disorders (EAHAD), the European Haemophilia Consortium (EHC), and the World Federation of Hemophilia (WFH) have issued updated guidance to improve liver care for individuals with congenital bleeding disorders.

This new guidance, published in the Journal of Thrombosis and Haemostasis, was developed by a team of experts in liver disease, bleeding disorders, and patient advocacy. It provides recommendations for managing liver health and preventing complications such as liver cancer, cirrhosis, and liver failure.

In the past, people with bleeding disorders who underwent replacement therapy were at higher risk for viral hepatitis and liver damage. Advances in bleeding treatments and antiviral medications have greatly reduced these risks, but liver health remains affected by factors like alcohol use, metabolic conditions, and the severity of existing liver disease.

The guidelines offer practical advice for preventing and addressing these liver issues, helping ensure better care for those with congenital bleeding disorders.

For more information, read the full manuscript here: https://www.jthjournal.org/article/S1538-7836(24)00533-6/fulltext